[go: up one dir, main page]

UA89038C2 - Pyrrolotriazine compounds as kinase inhibitors - Google Patents

Pyrrolotriazine compounds as kinase inhibitors

Info

Publication number
UA89038C2
UA89038C2 UAA200608400A UAA200608400A UA89038C2 UA 89038 C2 UA89038 C2 UA 89038C2 UA A200608400 A UAA200608400 A UA A200608400A UA A200608400 A UAA200608400 A UA A200608400A UA 89038 C2 UA89038 C2 UA 89038C2
Authority
UA
Ukraine
Prior art keywords
compounds
formula
kinase inhibitors
useful
growth factor
Prior art date
Application number
UAA200608400A
Other languages
English (en)
Ukrainian (uk)
Inventor
Брайен Е. Финк
Ашвиникумар В. Гаваи
Григори Д. Вайт
Пинг Чен
Гарольд Масталерц
Дерек Дж. Норрис
Джон С. Токарски
Юфен Жао
Вен-Чинг Хан
Original Assignee
Бристол-Майэрс Сквибб Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бристол-Майэрс Сквибб Компани filed Critical Бристол-Майэрс Сквибб Компани
Publication of UA89038C2 publication Critical patent/UA89038C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Данное изобретение обеспечивает соединения формулы () и их фармацевтически приемлемые соли. Соединения формулы () ингибируют активность тирозинкиназы рецепторов фактора роста, таких как HER1, HER2 и HER4, что делает их полезными в роли антипролиферативных агентов. Соединения формулы () также являются полезными для лечения других заболеваний, связанных с путями преобразования сигнала, которые привлекают рецепторы фактора роста.
UAA200608400A 2003-12-29 2004-12-23 Pyrrolotriazine compounds as kinase inhibitors UA89038C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53333503P 2003-12-29 2003-12-29

Publications (1)

Publication Number Publication Date
UA89038C2 true UA89038C2 (en) 2009-12-25

Family

ID=34748887

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200608400A UA89038C2 (en) 2003-12-29 2004-12-23 Pyrrolotriazine compounds as kinase inhibitors

Country Status (31)

Country Link
US (4) US7141571B2 (ru)
EP (2) EP1699797B1 (ru)
JP (1) JP4740878B2 (ru)
KR (1) KR100839716B1 (ru)
CN (1) CN1922182B (ru)
AR (1) AR047076A1 (ru)
AT (1) ATE443706T1 (ru)
AU (1) AU2004312413C1 (ru)
BR (1) BRPI0418231A (ru)
CA (1) CA2552107C (ru)
CL (1) CL2009001492A1 (ru)
CY (1) CY1109662T1 (ru)
DE (1) DE602004023324D1 (ru)
DK (1) DK1699797T3 (ru)
ES (1) ES2331842T3 (ru)
GE (1) GEP20105081B (ru)
HR (1) HRP20090601T1 (ru)
IL (1) IL176450A0 (ru)
MX (1) MXPA06007038A (ru)
MY (1) MY145634A (ru)
NO (1) NO20062763L (ru)
NZ (2) NZ548070A (ru)
PE (1) PE20050679A1 (ru)
PL (1) PL1699797T3 (ru)
PT (1) PT1699797E (ru)
RU (1) RU2373209C2 (ru)
SI (1) SI1699797T1 (ru)
TW (1) TWI332840B (ru)
UA (1) UA89038C2 (ru)
WO (1) WO2005066176A1 (ru)
ZA (1) ZA200605160B (ru)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867300B2 (en) * 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
PT1497019E (pt) * 2002-04-23 2015-09-10 Bristol Myers Squibb Co Compostos de pirrolotriazina anilina úteis como inibidores de quinase
US20060014741A1 (en) * 2003-12-12 2006-01-19 Dimarco John D Synthetic process, and crystalline forms of a pyrrolotriazine compound
MY145634A (en) * 2003-12-29 2012-03-15 Bristol Myers Squibb Co Pyrrolotriazine compounds as kinase inhibitors
US7102002B2 (en) 2004-06-16 2006-09-05 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US20050288290A1 (en) * 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
US7253167B2 (en) * 2004-06-30 2007-08-07 Bristol-Myers Squibb Company Tricyclic-heteroaryl compounds useful as kinase inhibitors
TW200600513A (en) * 2004-06-30 2006-01-01 Bristol Myers Squibb Co A method for preparing pyrrolotriazine compounds
US7504521B2 (en) * 2004-08-05 2009-03-17 Bristol-Myers Squibb Co. Methods for the preparation of pyrrolotriazine compounds
PE20060421A1 (es) 2004-08-12 2006-06-01 Bristol Myers Squibb Co Procedimiento para preparar un compuesto de pirrolotriazina anilina como inhibidores de cinasa
TW200635927A (en) * 2004-12-22 2006-10-16 Bristol Myers Squibb Co Synthetic process
DE602006004976D1 (de) 2005-03-28 2009-03-12 Bristol Myers Squibb Co Kompetitive atp-kinasehemmer
US20060235020A1 (en) * 2005-04-18 2006-10-19 Soojin Kim Process for preparing salts of 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide and novel stable forms produced therein
MY150958A (en) 2005-06-16 2014-03-31 Astrazeneca Ab Compounds for the treatment of multi-drug resistant bacterial infections
WO2007064932A2 (en) * 2005-12-02 2007-06-07 Bayer Healthcare Llc. Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase
US8063208B2 (en) * 2006-02-16 2011-11-22 Bristol-Myers Squibb Company Crystalline forms of (3R,4R)-4-amino-1-[[4-[(3-methoxyphenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol
US20100136137A1 (en) * 2006-11-01 2010-06-03 Bristol-Meyers Squibb Company Therapeutic combination of a panher/vegfr2 kinase inhibitor and a platinum compound
ATE518946T1 (de) 2007-02-08 2011-08-15 Codexis Inc Ketoreduktasen und anwendungen davon
US20090076034A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched bms-690514
AU2008343062B2 (en) * 2007-12-19 2013-03-07 Genentech, Inc. 8-Anilinoimidazopyridines and their use as anti-cancer and/or anti-inflammatory agents
JP2010209058A (ja) * 2008-09-29 2010-09-24 Sumitomo Chemical Co Ltd １−置換−トランス−４−（置換アミノ）ピペリジン−３−オールの製造方法
JP5592890B2 (ja) * 2008-10-08 2014-09-17 ブリストル−マイヤーズ スクイブ カンパニー ピロロトリアジンキナーゼ阻害剤
TW201035100A (en) 2008-12-19 2010-10-01 Cephalon Inc Pyrrolotriazines as ALK and JAK2 inhibitors
CN102361863B (zh) 2009-01-21 2014-12-03 巴斯利尔药物股份公司 新的二环抗生素
IN2012DN01251A (ru) * 2009-07-28 2015-05-15 Ube Industries
CA2788355C (en) 2010-02-18 2018-03-06 Devi Reddy Gohimukkula Phenyl-heteroaryl derivatives and methods of use thereof
AU2011272198B2 (en) 2010-06-30 2016-09-22 Fujifilm Corporation Novel nicotinamide derivatives or salts thereof
CN102153558B (zh) * 2011-02-23 2012-11-21 扬州永济医药新技术有限公司 多靶点抗肿瘤抑制剂2-氨吡咯-三嗪的衍生物及其合成方法
DE102011119127A1 (de) * 2011-11-22 2013-05-23 Merck Patent Gmbh 3-Cyanaryl-1H-pyrrolo[2.3-b]pyridin-Derivate
CN103450204B (zh) 2012-05-31 2016-08-17 中国科学院上海药物研究所 吡咯[2，1-f][1，2，4]并三嗪类化合物，其制备方法及用途
US9724352B2 (en) 2012-05-31 2017-08-08 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Pyrrolo[2,1-F[1,2,4]triazine compounds, preparation methods and applications thereof
TW201414737A (zh) 2012-07-13 2014-04-16 必治妥美雅史谷比公司 作爲激酶抑制劑之咪唑并三□甲腈
WO2015054358A1 (en) 2013-10-11 2015-04-16 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
NZ722019A (en) * 2014-01-13 2022-07-01 Aurigene Discovery Tech Ltd Bicyclic heterocyclyl derivatives as irak4 inhibitors
US9459267B2 (en) * 2014-05-12 2016-10-04 Quest Diagnostics Investments Incorporated Quantitation of tamoxifen and metabolites thereof by mass spectrometry
AR112027A1 (es) 2017-06-15 2019-09-11 Biocryst Pharm Inc Inhibidores de alk 2 quinasa que contienen imidazol
WO2019214651A1 (zh) * 2018-05-08 2019-11-14 南京明德新药研发有限公司 作为选择性HER2抑制剂的吡咯并[2,1-f][1,2,4]三嗪类衍生物及其应用
WO2021088987A1 (zh) * 2019-11-08 2021-05-14 南京明德新药研发有限公司 作为选择性her2抑制剂的盐型、晶型及其应用
CN116323630A (zh) 2020-08-24 2023-06-23 吉利德科学公司 磷脂化合物及其用途
US20240132521A1 (en) * 2022-08-22 2024-04-25 Iambic Therapeutics, Inc. Compounds and methods for modulating her2
CN120271495B (zh) * 2025-06-12 2025-09-19 成都道合尔医药技术有限公司 一种(3r,4r)-n-pg-4-氨基-3-甲基哌啶的合成方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2127274C1 (ru) * 1992-09-25 1999-03-10 Эли Лилли Энд Компани СПОСОБ ПОЛУЧЕНИЯ 5-ЗАМЕЩЕННЫХ ПИРРОЛО (2,3-α)ПИРИМИДИНОВ
CA2163399A1 (en) 1994-11-24 1996-05-25 Katsuhiro Kawano Triazine derivative, chymase activity inhibitor and nitric oxide production inhibitor
NZ333302A (en) 1996-08-28 2000-08-25 Pfizer Substituted 6,5-hetero-bicyclic derivatives for the prevention or inhibition of a disorder that can be treated by antagonising corticotropin releasing factor
CA2373990C (en) * 1999-05-21 2007-05-08 Bristol-Myers Squibb Company Pyrrolotriazine inhibitors of kinases
US6982265B1 (en) 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
US6787545B1 (en) * 1999-08-23 2004-09-07 Shiongi & Co., Ltd. Pyrrolotriazine derivatives having spla2-inhibitory activities
US6867300B2 (en) * 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
US6670357B2 (en) * 2000-11-17 2003-12-30 Bristol-Myers Squibb Company Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
IL155570A0 (en) 2000-11-17 2003-11-23 Bristol Myers Squibb Co Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
TW200300350A (en) * 2001-11-14 2003-06-01 Bristol Myers Squibb Co C-5 modified indazolylpyrrolotriazines
ATE418546T1 (de) 2002-04-23 2009-01-15 Bristol Myers Squibb Co Als kinase inhibitoren geeignete arylketonpyrrolotriazin-verbindungen
PT1497019E (pt) 2002-04-23 2015-09-10 Bristol Myers Squibb Co Compostos de pirrolotriazina anilina úteis como inibidores de quinase
US6894066B2 (en) 2002-05-09 2005-05-17 Bernard Charles Sherman Magnesium salt of S-omeprazole
TW200407143A (en) 2002-05-21 2004-05-16 Bristol Myers Squibb Co Pyrrolotriazinone compounds and their use to treat diseases
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
US6933386B2 (en) 2002-07-19 2005-08-23 Bristol Myers Squibb Company Process for preparing certain pyrrolotriazine compounds
AU2003265349A1 (en) 2002-08-02 2004-02-23 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
TW200420565A (en) * 2002-12-13 2004-10-16 Bristol Myers Squibb Co C-6 modified indazolylpyrrolotriazines
US7102001B2 (en) 2003-12-12 2006-09-05 Bristol-Myers Squibb Company Process for preparing pyrrolotriazine
US7064203B2 (en) 2003-12-29 2006-06-20 Bristol Myers Squibb Company Di-substituted pyrrolotriazine compounds
MY145634A (en) * 2003-12-29 2012-03-15 Bristol Myers Squibb Co Pyrrolotriazine compounds as kinase inhibitors
US7102002B2 (en) 2004-06-16 2006-09-05 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7102003B2 (en) 2004-07-01 2006-09-05 Bristol-Myers Squibb Company Pyrrolotriazine compounds
US7151176B2 (en) 2004-10-21 2006-12-19 Bristol-Myers Squibb Company Pyrrolotriazine compounds

Also Published As

Publication number Publication date
AU2004312413A1 (en) 2005-07-21
ATE443706T1 (de) 2009-10-15
CL2009001492A1 (es) 2010-01-15
TWI332840B (en) 2010-11-11
US20050182058A1 (en) 2005-08-18
AR047076A1 (es) 2006-01-04
TW200526226A (en) 2005-08-16
MXPA06007038A (es) 2006-08-31
RU2006127396A (ru) 2008-02-10
ES2331842T3 (es) 2010-01-18
CN1922182A (zh) 2007-02-28
RU2373209C2 (ru) 2009-11-20
US7846931B2 (en) 2010-12-07
WO2005066176A1 (en) 2005-07-21
HRP20090601T1 (hr) 2009-12-31
NO20062763L (no) 2006-09-11
US20110039838A1 (en) 2011-02-17
US7297695B2 (en) 2007-11-20
CN1922182B (zh) 2010-08-18
JP2007518721A (ja) 2007-07-12
US20060264438A1 (en) 2006-11-23
BRPI0418231A (pt) 2007-04-27
EP1699797A1 (en) 2006-09-13
DE602004023324D1 (de) 2009-11-05
PE20050679A1 (es) 2005-09-25
CA2552107A1 (en) 2005-07-21
ZA200605160B (en) 2007-12-27
NZ548070A (en) 2009-02-28
NZ573544A (en) 2010-04-30
JP4740878B2 (ja) 2011-08-03
HK1088332A1 (en) 2006-11-03
EP2058314A1 (en) 2009-05-13
US7141571B2 (en) 2006-11-28
MY145634A (en) 2012-03-15
EP1699797B1 (en) 2009-09-23
GEP20105081B (en) 2010-09-27
US20090048244A1 (en) 2009-02-19
SI1699797T1 (sl) 2010-04-30
AU2004312413B2 (en) 2010-07-22
KR20060107828A (ko) 2006-10-16
IL176450A0 (en) 2006-10-05
PL1699797T3 (pl) 2010-02-26
AU2004312413C1 (en) 2011-01-27
KR100839716B1 (ko) 2008-06-19
CY1109662T1 (el) 2014-08-13
CA2552107C (en) 2011-10-18
DK1699797T3 (da) 2010-01-04
PT1699797E (pt) 2009-12-29

Similar Documents

Publication Publication Date Title
UA89038C2 (en) Pyrrolotriazine compounds as kinase inhibitors
TW200420565A (en) C-6 modified indazolylpyrrolotriazines
MXPA04004492A (es) Indazolilpirrolotriazinas c-5 modificadas.
MXPA05000715A (es) Inhibidores novedosos de cinasas.
WO2004001059A3 (en) Heterocyclic inhibitors of kinases
WO2005065266A3 (en) Di-substituted pyrrolotriazine compounds
WO2006007378A3 (en) Pyrrolotriazine kinase inhibitors
SG132683A1 (en) Imidazopyrazine tyrosine kinase inhibitors
WO2004009542A3 (en) Process for preparing certain pyrrolotriazine compounds
MY128370A (en) Pyrrolotriazane inhibitors of kinases
TW200613306A (en) Imidazotriazines as protein kinase inhibitors
YU84603A (sh) Novi inhibitori tirozin kinaze
MXPA04004107A (es) Moleculas pequenas para el tratamiento del crecimiento celular anormal.
MXPA02012681A (es) Compuestos de sales de ditosilato de quinazolina.
MXPA05010621A (es) Pirimidinonas sustituidas.
TW200519096A (en) Quinazoline analogs as receptor tyrosine kinase inhibitors
EP1773791A4 (en) PYRROLOTRIAZINVERBINDUNGEN
MXPA06009475A (es) Derivados de quinazolina y usos terapeuticos de los mismos.
UA85394C2 (ru) Замещенные хинолины в качестве ингибиторов ферментов протеинтирозиновых киназ
WO2005058245A3 (en) Synthetic process
MXPA04005809A (es) Inhibidores de proteinas quinasas.
UA90659C2 (ru) Аналоги хиназолина как ингибиторы рецепторных тирозинкиназ
NO20072667L (no) Fremstillingsmetode
ATE421510T1 (de) Kompetitive atp-kinasehemmer
WO2006135796A3 (en) Crystalline forms of a pyrrolotriazine compound